Profile data is unavailable for this security.
About the company
Cue Biopharma Inc is a development-stage immunotherapy company. The Company is focused at developing biologics engineered to selectively modulate disease-relevant T cell subsets to treat cancer and autoimmune disease. Its Immuno-Oncology pipeline includes CUE-100 Framework, and CUE-200 Framework; and autoimmune pipeline includes MHC Class I Program, and MHC Class II Program. The CUE-100 Framework restricts the activity of T cell populations. The CUE-200 Framework enables potent, long-lived anti-tumor T cell responses. The Autoimmune disease therapy protects the healthy cells from immune attack.
- Revenue in USD (TTM)9.35m
- Net income in USD-46.80m
- Incorporated2014
- Employees57.00
- LocationCue Biopharma Inc40 Guest StreetBOSTON 02135United StatesUSA
- Phone+1 (617) 949-2680
- Fax+1 (302) 655-5049
- Websitehttps://www.cuebiopharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Inotiv Inc | 586.20m | -341.29m | 119.19m | 2.10k | -- | 0.424 | -- | 0.2033 | -13.33 | -13.33 | 22.98 | 10.97 | 0.6253 | 7.64 | 8.00 | 279,275.40 | -36.35 | -35.01 | -41.73 | -44.47 | 27.22 | 29.67 | -58.13 | -43.25 | 1.01 | 0.1699 | 0.5716 | -- | 511.19 | 86.55 | -3,193.33 | -- | 153.46 | -- |
| CytomX Therapeutics Inc | 71.94m | -97.59m | 122.92m | 174.00 | -- | 4.31 | -- | 1.71 | -1.49 | -1.49 | 1.10 | 0.4318 | 0.2407 | -- | 55.36 | 413,465.50 | -32.65 | -20.40 | -48.78 | -26.44 | -- | -- | -135.65 | -103.79 | -- | -- | 0.00 | -- | -30.68 | 35.84 | -154.25 | -- | -5.86 | -- |
| Carisma Therapeutics Inc | 40.00m | -19.88m | 125.59m | 17.00 | -- | 4.00 | -- | 3.14 | -0.0991 | -0.0991 | 0.1991 | 0.7802 | 0.1861 | -- | 3.81 | 2,352,941.00 | -9.25 | -25.47 | -10.27 | -27.87 | -- | -- | -49.71 | -236.32 | -- | -- | 0.00 | -- | 50.69 | 148.16 | -5,817.86 | -- | -- | -- |
| ProPhase Labs Inc | 145.98m | 31.50m | 125.83m | 129.00 | 5.25 | 1.82 | 3.45 | 0.862 | 1.47 | 1.47 | 6.74 | 4.24 | 1.71 | 9.24 | 6.02 | 1,131,628.00 | 36.95 | -0.7853 | 43.78 | -0.9393 | 57.53 | 44.25 | 21.58 | -0.9262 | 3.92 | 47.39 | 0.1054 | -- | 444.59 | 79.80 | 369.69 | -- | 45.40 | -- |
| Anixa Biosciences Inc | 0.00 | -13.60m | 126.17m | 4.00 | -- | 4.34 | -- | -- | -0.4478 | -0.4478 | 0.00 | 0.9396 | 0.00 | -- | -- | 0.00 | -41.31 | -80.77 | -42.45 | -85.60 | -- | -- | -- | -3,362.83 | -- | -- | 0.00 | -- | -100.00 | -- | -4.95 | -- | -- | -- |
| Annovis Bio Inc | 0.00 | -28.15m | 126.62m | 3.00 | -- | 4.23 | -- | -- | -3.45 | -3.45 | 0.00 | 3.67 | 0.00 | -- | -- | 0.00 | -70.25 | -- | -73.60 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -165.23 | -- | -- | -- |
| Personalis Inc | 65.05m | -113.32m | 127.59m | 395.00 | -- | 0.5845 | -- | 1.96 | -2.48 | -2.48 | 1.42 | 4.67 | 0.1888 | 7.28 | 3.71 | 164,676.00 | -32.88 | -26.39 | -36.27 | -33.83 | 20.52 | 29.81 | -174.20 | -79.72 | 5.77 | -- | 0.0118 | -- | -23.92 | 47.26 | -73.73 | -- | 57.44 | -- |
| Veru Inc | 27.73m | -114.24m | 129.05m | 233.00 | -- | 2.63 | -- | 4.65 | -1.42 | -1.42 | 0.3455 | 0.609 | 0.201 | 1.21 | 4.65 | 119,000.00 | -82.80 | -30.72 | -102.95 | -37.95 | 70.15 | 73.21 | -412.01 | -68.79 | 1.60 | -115.31 | 0.1995 | -- | -35.76 | 23.58 | -1,232.97 | -- | 40.58 | -- |
| Cue Biopharma Inc | 9.35m | -46.80m | 130.85m | 57.00 | -- | 2.12 | -- | 14.00 | -1.38 | -1.38 | 0.2763 | 1.43 | 0.1205 | -- | 11.93 | 164,006.50 | -60.32 | -56.36 | -72.23 | -65.49 | -- | -- | -500.65 | -827.70 | -- | -- | 0.164 | -- | 373.68 | -- | 1.39 | -- | 12.09 | -- |
| RVL Pharmaceuticals PLC | 42.77m | -53.05m | 130.88m | 156.00 | -- | 1.91 | -- | 3.06 | -0.6251 | -0.6257 | 0.5020 | 0.6913 | 0.3229 | 11.04 | 15.39 | 274,192.30 | -40.05 | -18.78 | -55.99 | -21.86 | 81.35 | 51.85 | -124.02 | -61.82 | 3.27 | -90.10 | 0.4493 | -- | -90.16 | -39.64 | -4.10 | -- | -35.47 | -- |
| ESSA Pharma Inc | 0.00 | -32.75m | 130.95m | 50.00 | -- | 0.8083 | -- | -- | -0.7433 | -0.7433 | 0.00 | 3.67 | 0.00 | -- | -- | 0.00 | -18.37 | -27.41 | -18.72 | -28.52 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 4.62 | -- | -- | -- |
| Enzolytics Inc | 0.00 | -119.19k | 132.75m | 2.00 | -- | -- | -- | -- | -0.106 | -0.106 | 0.00 | -1.04 | 0.00 | -- | -- | -- | -369.52 | -- | -- | -- | -- | -- | -- | -- | -- | -4.30 | -- | -- | -100.00 | -- | -9.35 | -- | -- | -- |
| Shattuck Labs Inc | 652.00k | -101.95m | 139.23m | 105.00 | -- | 0.7893 | -- | 213.55 | -2.41 | -2.41 | 0.0154 | 4.16 | 0.0026 | -- | -- | 6,209.52 | -40.46 | -- | -44.87 | -- | -- | -- | -15,635.74 | -- | -- | -- | 0.00 | -- | -97.83 | -- | -126.68 | -- | -- | -- |
| Reneo Pharmaceuticals Inc | 0.00 | -48.96m | 140.06m | 32.00 | -- | 1.25 | -- | -- | -2.00 | -2.00 | 0.00 | 4.57 | 0.00 | -- | -- | 0.00 | -34.31 | -- | -36.32 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -104.32 | -- | -- | -- |
| Y-mAbs Therapeutics Inc | 43.42m | -133.62m | 140.17m | 148.00 | -- | 1.30 | -- | 3.23 | -3.06 | -3.06 | 0.9935 | 2.47 | 0.2262 | 1.25 | 5.26 | 293,364.90 | -69.61 | -44.96 | -81.84 | -49.55 | 84.09 | -- | -307.75 | -571.59 | 3.97 | -- | 0.00 | -- | 68.18 | -- | 53.68 | -- | -- | -- |
Data as of Mar 20 2023. Currency figures normalised to Cue Biopharma Inc's reporting currency: US Dollar USD
21.83%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Slate Path Capital LPas of 31 Dec 2022 | 2.40m | 5.58% |
| Prosight Management LPas of 31 Dec 2022 | 1.84m | 4.28% |
| The Vanguard Group, Inc.as of 31 Dec 2022 | 1.52m | 3.53% |
| Bleichroeder LPas of 31 Dec 2022 | 861.28k | 2.00% |
| BlackRock Fund Advisorsas of 31 Dec 2022 | 602.62k | 1.40% |
| Monaco Asset Management SAMas of 31 Dec 2022 | 497.18k | 1.16% |
| Robertson Stephens Wealth Management LLC (Invt Mgmt)as of 31 Dec 2022 | 478.50k | 1.11% |
| Dimensional Fund Advisors LPas of 31 Dec 2022 | 457.67k | 1.06% |
| Millennium Management LLCas of 31 Dec 2022 | 373.98k | 0.87% |
| Carlson Capital LPas of 31 Dec 2022 | 365.00k | 0.85% |
More ▼
Data from 31 Dec 2022 - 31 Dec 2022Source: FactSet Research Systems Inc.
